| Contents per vial | 10 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99,14 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813,45 g/mol |
| Sequence or structure | Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQKAFVQWLIAGGPSSGAPPPS-NH₂ |
| CAS | 2023788-19-2 |
| Intended use | For laboratory research only |
About this product
Tirzepatide is a dual agonist of GIP and GLP-1 receptors. The research of the active substance is mainly connected with the regulation of glycemia and body weight. The combination of the two incretin pathways influences satiety, food intake and insulin response. Significant weight reduction and improvement in metabolic parameters are observed in studies.
What is TIRZEPATIDE?
TIRZEPATIDE is classified as a substance of the type ‘synthetic peptide or peptide analog’ and is evaluated in scientific research in relation to areas such as body weight reduction and regulation, decreased appetite and increased satiety, glucose control and fat metabolism. Attention is paid to its interaction with relevant receptors, enzymes or cellular pathways and subsequent changes in measurable laboratory parameters.
Mechanism of action under investigation
Tirzepatide activates GIP and GLP-1 receptors. These receptors link the digestive tract, pancreas and central nervous system and influence insulin, glucagon, satiety and food intake.
MAIN AREAS OF RESEARCH
• Weight management: The SURMOUNT program is investigating Tirzepatide in obesity and overweight, monitoring the change in body weight, waist circumference and long-term maintenance of the achieved reduction.
• Appetite and satiety: Activation of GIP and GLP-1 receptors affects satiety signals and energy intake, which is one of the mechanisms associated with changes in body weight.
• Glucose control: The SURPASS program focuses on HbA1c, fasting blood glucose and insulin response in people with type 2 diabetes.
• MASH and liver fibrosis: The SYNERGY-NASH trial is evaluating Tirzepatide in metabolic inflammatory liver disease, including biopsy-proven changes in MASH and the degree of fibrosis.
• Prediabetes and metabolic risk: Long-term follow-up examines how the risk of progression to type 2 diabetes changes in people with obesity and prediabetes, alongside other metabolic indicators.
Research findings to date
Work to date with the substance TIRZEPATIDE is devoted to areas that include reduction and regulation of body weight, reduction of appetite and increase of satiety, glucose control, fat metabolism, cardiometabolic risk. The research of the active substance is mainly connected with the regulation of glycemia and body weight. Significant weight reduction and improvement in metabolic parameters are observed in studies.
In the clinical use of tirzepatide, nausea, diarrhea, vomiting, constipation and abdominal pain are among the frequent side effects. With substances affecting glucose, the risk of hypoglycemia is also monitored, especially in combination with other drugs.
